Curated News
By: NewsRamp Editorial Staff
December 28, 2024
Investors Alerted to Securities Class Action Against Kyverna Therapeutics, Inc.
Discuss on Reddit
Telegram
GithubTLDR
- Act now to join the class action lawsuit against Kyverna Therapeutics, Inc. before the lead plaintiff deadline on February 7, 2025.
- Kyverna investors can seek appointment as a lead plaintiff representative through Kessler Topaz Meltzer & Check, LLP by February 7, 2025.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from corporate misconduct and recover losses for victims of fraud.
- Kyverna Therapeutics, Inc. faces a securities class action lawsuit for allegedly making false statements related to one of its clinical trials.
Impact - Why it Matters
This news matters as it highlights potential misconduct by Kyverna Therapeutics, Inc. that may have led to investor losses. Investors who purchased Kyverna stock during its IPO should take note of the lawsuit and consider their options before the lead plaintiff deadline on February 7, 2025.
Summary
The law firm of Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Kyverna Therapeutics, Inc. on behalf of investors who purchased Kyverna common stock during its IPO. The lawsuit alleges that Kyverna made false statements regarding adverse data related to one of its clinical trials, leading to investor losses.
Investors have until February 7, 2025, to seek appointment as a lead plaintiff representative through Kessler Topaz Meltzer & Check, LLP. The firm encourages affected investors to contact them for more information and to potentially participate in the legal proceedings.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Investors Alerted to Securities Class Action Against Kyverna Therapeutics, Inc.
